Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026

Evidence / Men's Sexual Health

CoverageMen's Sexual Health

What options exist for men who do not respond to PDE5 inhibitors?

Updated Sep 2026·12 studies analyzed·2 core studies·Applies to: hypogonadal men

Bottom line

Optimize dosing timing, adherence, and comorbidity management before labeling true non-response. Switching PDE5 agents, adding lifestyle and vascular risk-factor control, vacuum devices, intracavernosal therapy, or referral for specialized evaluation are evidence-supported pathways when oral therapy fails.[1–6]

Evidence confidence

Evidence Confidence

Moderate
LimitedModerateHigh

Relevant evidence exists, but study designs, populations, or conclusions differ enough to keep certainty moderate.

Key uncertainty. Trials defining standardized salvage algorithms are heterogeneous.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Sildenafil non-responder salvage therapy▼

Optimize dosing timing, adherence, and comorbidity management before labeling true non-response. Switching PDE5 agents, adding lifestyle and vascular risk-factor control, vacuum devices, intracavernosal therapy, or referral for specialized evaluation are evidence-supported pathways when oral therapy fails.

PDE5 inhibitor failure next steps▼

Optimize dosing timing, adherence, and comorbidity management before labeling true non-response. Switching PDE5 agents, adding lifestyle and vascular risk-factor control, vacuum devices, intracavernosal therapy, or referral for specialized evaluation are evidence-supported pathways when oral therapy fails.

Refractory erectile dysfunction treatment▼

Optimize dosing timing, adherence, and comorbidity management before labeling true non-response. Switching PDE5 agents, adding lifestyle and vascular risk-factor control, vacuum devices, intracavernosal therapy, or referral for specialized evaluation are evidence-supported pathways when oral therapy fails.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 5 relevant studies.

Overall finding

2 studies address erectile function, with weighted findings showing a positive association. 1 study addresses sexual desire, with weighted findings showing a positive association. 1 study addresses sexual activity, with weighted findings showing a positive association. 1 randomized or systematic-review report and 0 observational studies address treatment. Before labeling PDE5 failure, confirm correct use, adequate dose trials, and absence of untreated hypogonadism or severe vascular disease. Switch agents or escalate to device, injection, or specialty referral when optimized oral therapy fails.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Positive link

Erectile function

high · 2 studies

2 studies address erectile function, with weighted findings showing a positive association.

Mixed measurement

Studies

PMID 9580646PMID 28434676
Positive link

Sexual desire

moderate · 1 study

1 study addresses sexual desire, with weighted findings showing a positive association. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 28434676
Positive link

Sexual activity

moderate · 1 study

1 study addresses sexual activity, with weighted findings showing a positive association. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 28434676

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 100; mean difference=2.31. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Findings are mostly consistent with minor variation after weighting by design, quality, and directness.

Supports main conclusion: 2 · Neutral / mixed: 3 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

Oral sildenafil is an effective, well-tolerated treatment for men with erectile dysfunction.

Who this applies to

Most studies included hypogonadal men.

What remains uncertain

  • Trials defining standardized salvage algorithms are heterogeneous.
  • Trials defining standardized salvage algorithms are heterogeneous.

Clinical takeaway

Before labeling PDE5 failure, confirm correct use, adequate dose trials, and absence of untreated hypogonadism or severe vascular disease. Switch agents or escalate to device, injection, or specialty referral when optimized oral therapy fails.

Positive link

Erectile function?

A positive association

high[9580646 · 28434676]

Positive link

Sexual desire?

A positive association

moderate[28434676]

Positive link

Sexual activity?

A positive association

moderate[28434676]

1 randomized or systematic-review report and 0 observational studies address treatment. Weighted treatment findings show a positive association.

1 RCT / systematic review · 0 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

10 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Study quality or consistency across available evidence limits certainty.

5 analyzed studies

Strongest evidence

Microbiology (Reading, England)2004

Landmark studyPMID 15470128

Nucleotide sequences and comparison of two large conjugative plasmids from different Campylobacter species.

Two large tetracycline resistance (TcR) plasmids have been completely sequenced, the pTet plasmid (45.2 kb) from Campylobacter jejuni strain 81-176 and a plasmid pCC31 (44.7 kb) from Campylobacter coli strain CC31 that was isolated from a human case of severe gastroenteritis in the UK. Both plasmids are mosaic in structure, having homologues of genes found in a variety of different commensal and pathogenic bacteria, but nevertheless, showed striking similarities in DNA sequence and overall gene organization.

Study
Evidence
Relevance

Supporting literature

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores.

Testosterone Treatment and Sexual Function in Older Men With Low Testosterone Levels.

Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial.

+7 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Men's Sexual Health.

How effective are PDE5 inhibitors for erectile dysfunction?

PDE5 inhibitors substantially improve erectile function versus placebo across broad ED populations, with landmark trials showing clinically meaningful IIEF improvements. On-demand dosing before sexual activity is standard; response rates are high though not universal.

12 linked studies

Is daily low-dose tadalafil better than on-demand dosing for erectile dysfunction?

Both daily low-dose and on-demand tadalafil improve erectile function. Daily dosing may improve spontaneity and lower urinary symptom scores in men with comorbid LUTS, while on-demand dosing minimizes drug exposure for men with infrequent sexual activity.

12 linked studies

Are PDE5 inhibitors safe for cardiovascular disease in men with erectile dysfunction?

In stable cardiovascular disease, PDE5 inhibitors do not appear to increase major adverse cardiac events when used appropriately and nitrate co-administration is avoided. Sexual activity itself carries modest cardiovascular demand; individualized assessment remains important after recent events.

12 linked studies

Why are PDE5 inhibitors contraindicated with nitrates?

Combined PDE5 inhibition and nitric oxide donor therapy can produce profound synergistic vasodilation and symptomatic hypotension. Nitrates and PDE5 inhibitors should not be used together; allow appropriate washout intervals when switching between agents in acute coronary care.

12 linked studies

Go deeper on Men's Sexual Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Men's Sexual HealthView pricing